2. Search Result
Search Result
Results for "

adipocytes differentiation

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

2

Peptides

18

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1844A
    Chemerin-9 (149-157) (TFA)
    4 Publications Verification

    		 Chemerin Receptor Akt ERK Reactive Oxygen Species Amyloid-β Inflammation/Immunology
    Chemerin-9 (149-157) TFA is a potent agonist of chemokine-like receptor 1 (CMKLR1) . Chemerin-9 (149-157) TFA has anti-inflammatory activity. Chemerin-9 (149-157) TFA stimulates phosphorylation of Akt and ERK as well as ROS production. Chemerin-9 (149-157) TFA ameliorates Aβ1-42-induced memory impairmen. Chemerin-9 (149-157) TFA regulates immune responses, adipocyte differentiation, and glucose metabolism .
    Chemerin-9 (149-157) (TFA)
  • HY-B1898
    Metadoxine

    		PKA Metabolic Disease
    Metadoxine blocks adipocyte differentiation in association with inhibition of the protein kinase A-cAMP response element binding protein (PKA-CREB) pathway.
    Metadoxine
  • HY-N2414
    Periplogenin
    1 Publications Verification

    		 Others Inflammation/Immunology
    Periplogenin is a naturally occurring furanocoumarin found in Angelica dahurica roots, with potent anti-psoriatic effects. Periplogenin induces adipocyte differentiation .
    Periplogenin
  • HY-N1185
    Tagitinin A

    		Others Metabolic Disease
    Tagitinin A is a sesquiterpene with anti-hyperglycemic activity. Tagitinin A significantly inhibits glucose uptake in differentiated 3T3-L1 adipocytes .
    Tagitinin A
  • HY-N0404
    Sinigrin
    1 Publications Verification

    		 p38 MAPK AMPK Metabolic Disease Inflammation/Immunology Cancer
    Sinigrin is a major glucosinolate present in plants of the Brassicaceae family. Sinigrin inhibits early-stage adipogenesis of 3T3-L1 adipocytes through the AMPK and MAPK signaling pathways. Sinigrin has potent anti-oxidant, anti-tumor and anti-inflammatory effects .
    Sinigrin
  • HY-N8099
    Pulsatilloside C

    		Others Metabolic Disease
    Pulsatilloside C is a compound isolated from Pulsatilla koreana. Pulsatilloside C significantly inhibits adipocyte differentiation .
    Pulsatilloside C
  • HY-E70251
    22:6 Coenzyme A

    Docosahexaenoyl coenzyme A triammonium

    		 Endogenous Metabolite Others
    22:6 Coenzyme A (Docosahexaenoyl coenzyme A triammonium) is a coenzyme that contains 22 carbon atoms and 6 unsaturated bonds. 22:6 Coenzyme A can serve as an acyl substrate and is used in research on the effects of lysophospholipid acyltransferase activities in adipocyte differentiation .
    22:6 Coenzyme A
  • HY-133556
    IQZ23

    		AMPK Metabolic Disease
    IQZ23 inhibits adipocyte differentiation via AMPK pathway activation. IQZ23 exerts a high efficacy in decreasing the triglyceride level (EC50=0.033 μM) in 3T3-L1 adipocytes. IQZ23 could be used for the research of obesity and related metabolic disorders .
    IQZ23
  • HY-N7661
    4β-Hydroxywithanolide E

    		PPAR Metabolic Disease
    4β-Hydroxywithanolide E, isolated from Physalis peruviana L., inhibits adipocyte differentiation of 3T3-L1 cells through modulation of mitotic clonal expansion. 4β-Hydroxywithanolide E is an adipogenesis inhibitor and inhibits PPARγ, C/EBPα, and the adipocyte-specific molecule aP2 mRNA expression .
    4β-Hydroxywithanolide E
  • HY-P1844
    Chemerin-9 (149-157)

    		Chemerin Receptor Akt ERK Reactive Oxygen Species Amyloid-β Inflammation/Immunology
    Chemerin-9 (149-157) is a potent agonist of chemokine-like receptor 1 (CMKLR1) . Chemerin-9 (149-157) has anti-inflammatory activity. Chemerin-9 (149-157) stimulates phosphorylation of Akt and ERK as well as ROS production. Chemerin-9 (149-157) ameliorates Aβ1-42-induced memory impairmen. Chemerin-9 (149-157) regulates immune responses, adipocyte differentiation, and glucose metabolism .
    Chemerin-9 (149-157)
  • HY-N0404R
    Sinigrin (Standard)

    		p38 MAPK AMPK Metabolic Disease Inflammation/Immunology
    Sinigrin (Standard) is the analytical standard of Sinigrin. This product is intended for research and analytical applications. Sinigrin is a major glucosinolate present in plants of the Brassicaceae family. Sinigrin inhibits early-stage adipogenesis of 3T3-L1 adipocytes through the AMPK and MAPK signaling pathways. Sinigrin has potent anti-oxidant, anti-tumor and anti-inflammatory effects .
    Sinigrin (Standard)
  • HY-E70259
    18:2 (n6) Coenzyme A triammonium

    		Endogenous Metabolite Metabolic Disease
    18:2 (n6) Coenzyme A triammonium is a Coenzyme A. 18:2 (n6) Coenzyme A triammonium can be used to determine the effects of lysophospholipid acyltransferase activities in adipocyte differentiation .
    18:2 (n6) Coenzyme A triammonium
  • HY-20019
    L-165041

    		PPAR Metabolic Disease
    L-165041 is a cell permeable PPARδ agonist, with Kis of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively, and induces adipocyte differentiation in NIH-PPARδ cells.
    L-165041
  • HY-128400
    4'-Methoxychalcone

    		PARP Metabolic Disease Cancer
    4'-Methoxychalcone regulates adipocyte differentiation through PPARγ activation. 4'-Methoxychalcone modulates the expression and secretion of various adipokines in adipose tissue that are involved in insulin sensitivity .
    4'-Methoxychalcone
  • HY-N2961
    Broussonin B

    		Others Others
    Broussonin B is a phenolic compound isolated from the stem barks of Broussonetia kanzinoki (Moraceae). Broussonin B inhibits adipocyte differentiation in 3T3-L1 cells .
    Broussonin B
  • HY-102082
    Adenosine N1-oxide

    		Others Inflammation/Immunology
    Adenosine N1-oxide is an oral active anti-inflammatory agent, and can be isolated from royal jelly. Adenosine N1-oxide promotes osteogenic and adipocyte differentiation .
    Adenosine N1-oxide
  • HY-117597
    YM440

    		Others Metabolic Disease
    YM440 is an orally active oxadiazolidinedione analog. YM440 ameliorates hyperglycemia without changing PPARy activity, adipocyte differentiation, or fat weight. YM440 is used in the study for non-insulin-dependent diabetes mellitus (NIDDM) .
    YM440
  • HY-N2177
    3-Dehydrotrametenolic acid

    		Lactate Dehydrogenase Apoptosis Cancer
    3-​Dehydrotrametenolic acid, isolated from the sclerotium of Poria cocos, is a lactate dehydrogenase (LDH) inhibitor. 3-​Dehydrotrametenolic acid promotes adipocyte differentiation in vitro and acts as an insulin sensitizer in vivo. 3-​Dehydrotrametenolic acid induces apoptosis and has anticancer activity .
    3-Dehydrotrametenolic acid
  • HY-N2551
    Vitamin U chloride

    S-Methylmethionine sulfonium chloride

    		 Others Inflammation/Immunology
    Vitamin U (S-Methylmethionine sulfonium) chloride is an orally active anti-ulcer agent with antioxidant activity. Vitamin U inhibits adipocyte differentiation. Vitamin U promotes skin wound healing.Vitamin U can be used in the research of gastrointestinal ulceration .
    Vitamin U chloride
  • HY-156093
    TPH1-IN-1

    		Tryptophan Hydroxylase Metabolic Disease
    TPH1-IN-1 (compound 40) is a xanthine derivative and an inhibitor of tryptophan hydroxylase TPH1 (IC50: 110.1 nM). TPH1-IN-1 has good in vitro activity and liver microsome stability, and effectively inhibits adipocyte differentiation of T3-L1 cells .
    TPH1-IN-1
  • HY-124822
    COH-SR4
    1 Publications Verification

    		 AMPK Metabolic Disease Cancer
    COH-SR4 is an AMPK activator. COH-SR4 shows potent anti-proliferative activities against leukemia, melanoma, breast and lung cancers. COH-SR4 inhibits adipocyte differentiation via AMPK activation. COH-SR4 can be used for the research of obesity and related metabolic disorders .
    COH-SR4
  • HY-142026
    Vitisin A

    (+)-Vitisin A

    		 NF-κB ERK Inflammation/Immunology
    Vitisin A has antioxidative, anticancer, antiapoptotic, neuroprotective and anti-inflammatory effects. Vitisin A inhibits LPS-induced NO and iNOS production via down-regulation of ERK1/2 and p38 and the NF-κB signal pathway. Vitisin A also inhibits adipocyte differentiation. Vitisin A is a resveratrol tetramer that can be isolated from Vitis vinifera roots .
    Vitisin A
  • HY-101292
    FK614

    		PPAR Metabolic Disease
    FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes .
    FK614
  • HY-N13160
    Sanggenon F

    		Others Metabolic Disease Inflammation/Immunology
    Sanggenon F is a flavonoid compound derived from Morus alba var. multicaulis. It inhibits the differentiation of 3T3-L1 adipocytes and the production of nitric oxide (NO) in RAW264.7 cells induced by lipopolysaccharides (HY-D1056) and IFN-γ (IC50 of 19 nM). Sanggenon F has potential application value in the fields of anti-inflammatory and metabolic diseases .
    Sanggenon F
  • HY-135982
    GPR81 agonist 1
    2 Publications Verification

    		 GPR109A Metabolic Disease
    GPR81 agonist 1 is a potent and highly selective GPR81 agonist, with EC50s of 58 nM and 50 nM for human and mouse GPR81, respectively. GPR81 agonist 1 inhibits lipolysis in differentiated 3T3-L1 adipocytes. GPR81 agonist 1 suppresses lipolysis in mice without cutaneous flushing. GPR81 agonist 1 displays remarkable selectivity for GPR81 over GPR109a .
    GPR81 agonist 1
  • HY-116538
    (10E,12Z)-Octadeca-10,12-dienoic acid

    trans-10,cis-12 CLA2

    		 Endogenous Metabolite PPAR Metabolic Disease Inflammation/Immunology Cancer
    (10E,12Z)-Octadeca-10,12-dienoic acidactivates PPAR α and inhibits adipocyte differentiation . (10E,12Z)-Octadeca-10,12-dienoic acid and its downstream metabolites have various antioxidant and antitumor activities. (10E,12Z)-Octadeca-10,12-dienoic acid is effective orally .
    (10E,12Z)-Octadeca-10,12-dienoic acid
  • HY-139282
    C16 1-Deoxyceramide (m18:1/16:0)

    C16:0 1-Deoxyceramide; C16:0 Ceramide (m18:1/16:0); Cer(m18:1/16:0)

    		 Endogenous Metabolite Metabolic Disease
    C16 1-Deoxyceramide (m18:1/16:0) (C16:0 1-Deoxyceramide) is a lipid molecule, which is composed of a long-chain fatty acid (16:0) and a 1-deoxysphingoid backbone. Deoxyceramide accumulates under the conditions of obesity and type 2 diabetes (T2D). Deoxyceramide is unable to be further metabolized to more complex sphingolipid, and is toxic when accumulates in the body. Deoxyceramide increases in differentiated adipocytes in vitro .
    C16 1-Deoxyceramide (m18:1/16:0)
  • HY-162866
    CXM102

    		Autophagy Metabolic Disease
    CXM102 is an autophagy activator. CXM102 can induce autophagy in aged BMSCs, leading to the rejuvenation of BMSCs and preferential differentiation into osteoblasts. CXM102 promotes the nuclear translocation of transcription factor EB (TFEB) and the formation of osteoblasts. CXM102 can stimulate bone synthesis metabolism in middle-aged male mice, reduce bone marrow adipocytes, delay bone loss, lower serum inflammation levels, decrease organ fibrosis, and extend the lifespan of the mice .
    CXM102
  • HY-139284
    C24:1 Dihydro 1-deoxyceramide (m18:0/24:1)

    C24:1 Deoxy dihydroceramide; C24:1 DeoxyDHceramide; Cer(m18:0/24:1)

    		 Endogenous Metabolite Metabolic Disease
    C24:1 Dihydro 1-deoxyceramide (m18:0/24:1) (C24:1 Deoxy dihydroceramide) is a lipid molecule, which is composed of a long-chain fatty acid (24:1) and a 1-deoxysphingoid backbone. Deoxyceramide accumulates under the conditions of obesity and type 2 diabetes (T2D). Deoxyceramide is unable to be further metabolized to more complex sphingolipid, and is toxic when accumulates in the body. Deoxyceramide increases in differentiated adipocytes in vitro .
    C24:1 Dihydro 1-deoxyceramide (m18:0/24:1)
  • HY-B0601
    Tafluprost acid
    1 Publications Verification

    AFP-172

    		 Prostaglandin Receptor Drug Metabolite Cardiovascular Disease Neurological Disease Endocrinology
    Tafluprost acid (AFP-172), an active metabolic form of Tafluprost, is a selective prostanoid FP receptor agonist. Tafluprost acid shows a high affinity for human prostanoid FP receptor with Ki and EC50 values of 0.4 nM and 0.53 nM, respectively. Tafluprost acid has 126 times weaker binding affinity for prostanoid EP3 receptor (IC50=67 nM) than for the prostanoid FP receptor. Tafluprost acid can be used in the research of glaucoma .
    Tafluprost acid
  • HY-139283
    C24:1 1-Deoxyceramide (m18:1/24:1(15Z))

    C24:1(15Z) 1-Deoxyceramide; C24:1 Ceramide (m18:1/24:1(15Z)); Cer(m18:1/24:1(15Z))

    		 Endogenous Metabolite Metabolic Disease
    C24:1 1-Deoxyceramide (m18:1/24:1(15Z)) (C24:1(15Z) 1-Deoxyceramide) is a lipid molecule, which is composed of a long-chain fatty acid (24:1) and a 1-deoxysphingoid backbone. Deoxyceramide accumulates under the conditions of obesity and type 2 diabetes (T2D). Deoxyceramide is unable to be further metabolized to more complex sphingolipid, and is toxic when accumulates in the body. Deoxyceramide increases in differentiated adipocytes in vitro .
    C24:1 1-Deoxyceramide (m18:1/24:1(15Z))
  • HY-N0704
    Agrimol B
    1 Publications Verification

    		 Sirtuin PPAR Fatty Acid Synthase (FASN) c-Myc Bacterial Infection Metabolic Disease Cancer
    Agrimol B, a polyphenol, is an orally active and potent SIRT1 activator. Agrimol B shows anti-adipogenic and anticancer activity. Agrimol B shows antibacterial activity against plant pathogens. Agrimol B dramatically inhibits 3T3-L1 adipocyte differentiation by reducing PPARγ, C/EBPα, FAS, UCP-1, and apoE expression. The action of Agrimol B on the cancer cells is likely derived from its effect on c-MYC, SKP2 and p27 .
    Agrimol B
  • HY-N11507
    Tibesaikosaponin V

    TKV

    		 PPAR Metabolic Disease
    Tibesaikosaponin V (TKV) is a triterpene diglycoside, which can be isolated from the methanol extract of the roots of Bupleurum chinense DC.. Tibesaikosaponin V inhibits lipid accumulation and triacylglycerol content occurred without cytotoxicity to adipocytes. Tibesaikosaponin V suppresses the mRNA expression of nuclear transcription factors, such as peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα). Tibesaikosaponin V inhibits 3T3-L1 preadipocyte differentiation. Tibesaikosaponin V can be used fro research of obesity and its associated metabolic disorders .
    Tibesaikosaponin V
  • HY-B1890R
    (±)-Catechin (Standard)

    		COX Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    (±)-Catechin (Standard) is the analytical standard of (±)-Catechin. This product is intended for research and analytical applications. (±)-Catechin (rel-Cianidanol) is the racemate of the green tea polyphenol Catechin. Catechin has anticancer activity and induces apoptosis. (±)-Catechin has two forms, (+)-Catechin and its enantiomer (-)-Catechin. (+)-Catechin inhibits cyclooxygenase-1 (COX-1) with an IC50 of 1.4 μM. (-)-Catechin can effectively promote hBM-MSC adipocyte differentiation and increase adiponectin and PPARγ levels. (±)-Catechin has anti-tumor, anti-obesity, anti-diabetic, anti-cardiovascular, anti-infectious, hepatoprotective and neuroprotective effects .
    (±)-Catechin (Standard)
  • HY-108568
    15-Deoxy-Δ-12,14-prostaglandin J2
    1 Publications Verification

    15d-PGJ2; 15-Deoxy-Δ12,14-PGJ2

    		 PPAR Endogenous Metabolite Neurological Disease Inflammation/Immunology Cancer
    15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM .
    15-Deoxy-Δ-12,14-prostaglandin J2
  • HY-100277R
    Mifobate (Standard)

    		PPAR Metabolic Disease
    Mifobate (Standard) is the analytical standard of Mifobate. This product is intended for research and analytical applications. Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC50=140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). Mifobate (SR-202) shows antiobesity and antidiabetic effects .
    Mifobate (Standard)
  • HY-100277
    Mifobate
    1 Publications Verification

    SR-202

    		 PPAR Metabolic Disease
    Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC50=140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). Mifobate (SR-202) shows antiobesity and antidiabetic effects .
    Mifobate
  • HY-116538R
    (10E,12Z)-Octadeca-10,12-dienoic acid (Standard)

    		Endogenous Metabolite PPAR Metabolic Disease Inflammation/Immunology Cancer
    (10E,12Z)-Octadeca-10,12-dienoic acid (Standard) is the analytical standard of (10E,12Z)-Octadeca-10,12-dienoic acid. This product is intended for research and analytical applications. (10E,12Z)-Octadeca-10,12-dienoic acidactivates PPAR α and inhibits adipocyte differentiation . (10E,12Z)-Octadeca-10,12-dienoic acid and its downstream metabolites have various antioxidant and antitumor activities. (10E,12Z)-Octadeca-10,12-dienoic acid is effective orally .
    (10E,12Z)-Octadeca-10,12-dienoic acid (Standard)
  • HY-108568S
    15-Deoxy-Δ-12,14-prostaglandin J2-d4

    15d-PGJ2-d4; 15-Deoxy-Δ12,14-PGJ2-d4

    		 PPAR Endogenous Metabolite Neurological Disease Inflammation/Immunology Cancer
    15-Deoxy-Δ-12,14-prostaglandin J2-d4 is the deuterium labeled 15-Deoxy-Δ-12,14-prostaglandin J2. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM[1][2].
    15-Deoxy-Δ-12,14-prostaglandin J2-d4
  • HY-108568R
    15-Deoxy-Δ-12,14-prostaglandin J2 (Standard)

    		PPAR Endogenous Metabolite Neurological Disease Inflammation/Immunology Cancer
    15-Deoxy-Δ-12,14-prostaglandin J2 (Standard) is the analytical standard of 15-Deoxy-Δ-12,14-prostaglandin J2. This product is intended for research and analytical applications. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 μM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM .
    15-Deoxy-Δ-12,14-prostaglandin J2 (Standard)
  • HY-W005130
    2,4,6-Trihydroxybenzaldehyde

    		NF-κB Metabolic Disease Cancer
    2,4,6-Trihydroxybenzaldehyde is an orally active NF-?B inhibitor. 2,4,6-Trihydroxybenzaldehyde shows anti-tumor activity, anti-cancer cell proliferative activity and anti-obesity activity .
    2,4,6-Trihydroxybenzaldehyde

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: